Arif Hussain

Affiliations: 
University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Biochemistry
Google:
"Arif Hussain"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pornour M, Jeon HY, Ryu H, et al. (2024) USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America. 121: e2403331121
Boyle J, Yau J, Slade JL, et al. (2024) Neighborhood Disadvantage and Prostate Tumor RNA Expression of Stress-Related Genes. Jama Network Open. 7: e2421903
Kango G, Malek R, Mannuel H, et al. (2024) Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology. Current Opinion in Oncology. 36: 195-201
Jeon HY, Pornour M, Ryu H, et al. (2023) SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research
Loehr A, Hussain A, Patnaik A, et al. (2022) Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. European Urology
Adediran S, Wang L, Khan MA, et al. (2022) Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. Cancers. 14
Hussain A, Jiang S, Varghese D, et al. (2022) Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. Bmc Cancer. 22: 304
Vogelzang NJ, Beer TM, Gerritsen W, et al. (2022) Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Jama Oncology
Loehr A, Patnaik A, Campbell D, et al. (2021) Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Denmeade SR, Wang H, Agarwal N, et al. (2021) TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002759
See more...